Basal insulin peglispro(Eli Lilly)(Basal insulin peglispro(Eli Lilly))

概要

基本信息

药物类型

激素

别名

BIL、Insulin peglispro、Pegylated insulin lispro

+ [1]

靶点

INSR

作用机制

INSR激动剂(胰岛素受体激动剂)

治疗领域

免疫系统疾病内分泌与代谢疾病

在研适应症-

非在研适应症

1型糖尿病2型糖尿病高血糖+ [1]

原研机构

Eli Lilly & Co.

在研机构-

非在研机构

Eli Lilly & Co.

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 31946

来源: *****

Sequence Code 4857

来源: *****

关联

38

项与 Basal insulin peglispro(Eli Lilly) 相关的临床试验

NCT02106364 / Withdrawn临床3期

A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naïve Patients With Type 2 Diabetes Mellitus: An Open-Label, Randomized, 52-week Study

The main purpose of this study is to compare the efficacy and safety of a new basal insulin, insulin peglispro, to insulin glargine in participants with type 2 diabetes mellitus (T2DM). Both drugs will be given by an injection under the skin. Participants may continue to take oral antihyperglycemic medication (OAM) during the study, as prescribed by their personal physician. The study is expected to last about 12 months for each participant.

开始日期2015-02-01

申办/合作机构

Eli Lilly & Co.

NCT02197520 / Completed临床1期

The Effect of Treatment With Basal Insulin Peglispro or Insulin Glargine on Insulin Sensitivity and the Effect of Prandial Insulin Lispro in Patients With Type 2 Diabetes Mellitus

This study will look into insulin sensitivity (how the body responds to insulin) and effects of meals on type 2 diabetics comparing insulin peglispro to insulin glargine. The study has two treatment periods, each of which will last about four weeks. One drug (insulin peglispro or insulin glargine) will be administered in each period. Participants will receive both drugs during the study. Participants may remain on stable dose metformin, as prescribed by their personal physician.

开始日期2014-07-01

申办/合作机构

Eli Lilly & Co.

NCT02152384 / Completed临床1期

The Effect of Treatment With Basal Insulin Peglispro or Insulin Glargine on the Dose Response Effect of Prandial Insulin Lispro in Patients With Type 1 Diabetes Mellitus.

This study will look into how a base dose of insulin peglispro and insulin glargine will affect the meal time dose and efficacy of insulin lispro in type 1 diabetics.

开始日期2014-06-01

申办/合作机构

Eli Lilly & Co.

100 项与 Basal insulin peglispro(Eli Lilly) 相关的临床结果

登录后查看更多信息

100 项与 Basal insulin peglispro(Eli Lilly) 相关的转化医学

登录后查看更多信息

100 项与 Basal insulin peglispro(Eli Lilly) 相关的专利（医药）

登录后查看更多信息

110

项与 Basal insulin peglispro(Eli Lilly) 相关的文献（医药）

2024-11-06·The Journal of Neuroscience

Selective Vulnerability of GABAergic Inhibitory Interneurons to Bilirubin Neurotoxicity in the Neonatal Brain

Article

作者: Liu, Zhen-Qi ; Mao, Lin-Fei ; Shi, Hai-Bo ; Yin, Xin-Lu ; Lai, Ke ; Liang, Min ; Liu, Han-Wei ; Gong, Li-Na ; Wang, Lu-Yang ; Yin, Shan-Kai ; Li, Ming-Xian ; Zhang, Zhen

Hyperbilirubinemia (HB) is a key risk factor for hearing loss in neonates, particularly premature infants. Here, we report that bilirubin (BIL)-dependent cell death in the auditory brainstem of neonatal mice of both sexes is significantly attenuated by ZD7288, a blocker for hyperpolarization-activated cyclic nucleotide-gated (HCN) channel-mediated current ( Ih ), or by genetic deletion of HCN1. GABAergic inhibitory interneurons predominantly express HCN1, on which BIL selectively acts to increase their intrinsic excitability and mortality by enhancing HCN1 activity and Ca 2+ -dependent membrane targeting. Chronic BIL elevation in neonatal mice in vivo increases the fraction of spontaneously active interneurons and their firing frequency, Ih , and death, compromising audition at the young adult stage in HCN1 +/+ , but not in HCN1 −/− genotype. We conclude that HB preferentially targets HCN1 to injure inhibitory interneurons, fueling a feedforward loop in which lessening inhibition cascades hyperexcitability, Ca 2+ overload, neuronal death, and auditory impairments. These findings rationalize HCN1 as a potential target for managing HB encephalopathy.

2024-11-01·International Journal of Biological Macromolecules

Bilobalide ameliorates osteoporosis by influencing the SIRT3/NF-κB axis in osteoclasts and promoting M2 polarization in macrophages

Article

作者: Zou, ChaoChun ; Jin, JiaLe ; Wang, DongYu ; Hu, ChenXi ; Xia, FangLing ; Ruan, ChenXin ; Qin, YiFang ; Guan, Ming ; Jiang, Chao ; Chao, YunQi

Osteoporosis is a systemic disease with complex etiology and high prevalence, resulting in a huge economic burden. For a long time, the search for new therapeutic pharmaceuticals has never stopped. Bone loss is related to the imbalance between bone resorption by osteoclasts and bone formation by osteoblasts. In recent years, the role of immunity and inflammation in the development of osteoporosis has studied well. For example, various cytokines, chemokines and endocrine factors regulate osteoclastogenesis via activating different macrophage subtypes, including pro-inflammatory M1 and anti-inflammatory M2. Bilobalide (Bil), an active Ginkgo biloba ingredient, has garnered great interest because of its anti-oxidant and anti-inflammatory activities. In this study, we found that Bil can attenuate osteoclast generation induced by receptor activator of nuclear factor- kappa B ligand (RANKL) through upregulating the sirtuin 3 (SIRT3) and negatively regulating NF-κB signaling. Furthermore, Bil promotes M2 polarization of macrophages in a dose-dependent manner. In vivo studies provided evidence that Bil improves bone density in osteoporosis mice models. Based on the above results, we have reason to believe that Bil has potential therapeutic value in osteoclast-mediated bone loss and offers an effective option for long-term osteoporosis management.

2024-10-01·Bioorganic Chemistry

Multi-component forms of the 2nd generation H1 receptor antagonist drug, Bilastine and its enhanced physicochemical characteristics

Article

作者: Kumar Bommaka, Manish ; Kar, Ananya ; Kenguva, Gowtham ; Bandi, Sreenivasulu ; Dandela, Rambabu ; Giri, Lopamudra

Bilastine (BIL) is a novel 2nd generation antihistamine medication is used to treat symptoms of chronic urticaria and allergic rhinitis. However, its poor solubility limits its therapeutic efficacy. In order to enhance the physicochemical characteristics of BIL, various molecular adducts of BIL (Salt, hydrate and co-crystal) were discovered in this study using two distinct salt-formers: Terephthalic acid (TA), 2,4-Dihydroxybenzoic acid (2,4-DHBA), and three nutraceuticals (Vanillic Acid (VA), Hydroquinone (HQN) and Hippuric acid (HA)). Various analytical methods were used to examine the synthesised adducts, including Powder X-Ray Diffraction (PXRD), Single Crystal X-ray Diffraction (SCXRD), and thermal analysis (Thermogravimetric analysis (TGA) and Differential Scanning Calorimetry (DSC)). Single-crystal X-ray diffraction (SCXRD) studies avowed that the architectures of the molecular adducts are maintained in the solid state by an array of strong (N⁺H⋯O^-, NH⋯O, OH⋯O) and weak (CH⋯O) hydrogen bonds. Additionally, a solubility test was performed to establish the in vitro release characteristics of newly synthesised BIL adducts and it observed that most of the molecular adducts exhibit higher rates of dissolution in comparison to pure BIL; in particular, BIL.TA.HYD showed the highest solubility and the fastest rate of dissolution. Moreover, experiments on flux permeability and diffusion demonstrated that the BIL.TA.HYD and BIL.VA salts had strong permeability and a high diffusion rate. In addition, the synthesized adduct's stability was assessed at 25 °C and 90 % ± 5 % relative humidity, and it was found that all the molecular salts were stable and did not undergo any phase changes or dissociation. The foregoing result leads us to believe that the newly synthesized molecular adducts' increased permeability and solubility will be advantageous for the creation of novel BIL formulations.

100 项与 Basal insulin peglispro(Eli Lilly) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11567

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高血糖	临床3期	南非	Eli Lilly & Co.	2011-11-01
高血糖	临床3期	英国	Eli Lilly & Co.	2011-11-01
高血糖	临床3期	波兰	Eli Lilly & Co.	2011-11-01
高血糖	临床3期	南非	Eli Lilly & Co.	2011-11-01
高血糖	临床3期	波多黎各	Eli Lilly & Co.	2011-11-01
高血糖	临床3期	波多黎各	Eli Lilly & Co.	2011-11-01
高血糖	临床3期	西班牙	Eli Lilly & Co.	2011-11-01
高血糖	临床3期	英国	Eli Lilly & Co.	2011-11-01
高血糖	临床3期	西班牙	Eli Lilly & Co.	2011-11-01
高血糖	临床3期	波兰	Eli Lilly & Co.	2011-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01784211 (CTgov)	临床1期	1型糖尿病	76	LY2605541 (LY2605541 (Part A))	襯鬱觸構積積鏇鹽網獵(齋鹹淵選顧廠壓糧壓襯) = 築鹽鏇鹽蓋遞獵鹽網廠簾襯衊築憲構獵廠鬱製 (鹹壓襯壓築築齋觸遞鏇, 膚蓋壓簾願艱糧夢觸製 ~ 夢襯憲膚醖鬱願齋構艱) 更多	-	2019-03-15
				Insulin Glargine (Glargine (Part A))	襯鬱觸構積積鏇鹽網獵(齋鹹淵選顧廠壓糧壓襯) = 鏇廠糧憲積鬱製衊夢願簾襯衊築憲構獵廠鬱製 (鹹壓襯壓築築齋觸遞鏇, 獵壓積憲繭壓鑰淵襯憲 ~ 窪繭淵鹽遞鏇願夢齋鏇) 更多
NCT01894568 (CTgov)	临床3期	2型糖尿病 \| 高血糖	388	Insulin Peglispro+Oral Antihyperglycemic Medications (OAMs) (Insulin Peglispro)	積襯醖壓積醖獵蓋積壓(蓋獵壓網鹹艱範艱積襯) = 顧蓋獵夢醖簾壓鹹製顧繭齋簾遞糧艱憲夢遞製 (鏇構窪廠膚憲遞廠夢醖, 遞繭鑰顧製鹹積淵膚齋 ~ 醖襯齋鏇鹽廠齋築製膚) 更多	-	2019-03-15
				Insulin Glargine+Oral Antihyperglycemic Medications (OAMs) (Insulin Glargine)	積襯醖壓積醖獵蓋積壓(蓋獵壓網鹹艱範艱積襯) = 醖鏇構夢鑰膚願夢糧蓋繭齋簾遞糧艱憲夢遞製 (鏇構窪廠膚憲遞廠夢醖, 鑰齋膚積鏇鹹餘簾餘齋 ~ 築網醖網構膚獵憲範廠) 更多
NCT01771250 (CTgov)	临床1期	1型糖尿病	15	Insulin Peglispro (Insulin Peglispro)	觸壓淵鹹衊壓選衊製淵(繭鑰艱選齋製糧鹽觸壓) = 顧網醖網醖鏇艱襯顧衊艱醖鑰鹹顧範衊夢齋艱 (網鹹鏇鹹顧願醖餘襯廠, 構願醖憲獵蓋淵夢遞鬱 ~ 醖廠膚網願糧襯衊網廠) 更多	-	2019-03-11
				insulin glargine (Insulin Glargine)	觸壓淵鹹衊壓選衊製淵(繭鑰艱選齋製糧鹽觸壓) = 簾廠築糧艱網膚壓壓鑰艱醖鑰鹹顧範衊夢齋艱 (網鹹鏇鹹顧願醖餘襯廠, 繭壓齋醖蓋積憲糧範窪 ~ 顧製鑰鑰鏇鹹積壓鏇艱) 更多
NCT02109029 (CTgov)	临床1期	1型糖尿病	24	Human Insulin	觸網齋獵築獵鏇獵選膚(選衊鑰膚鏇憲壓糧築壓) = 願蓋憲糧構觸艱齋夢構淵鹹獵膚鹹餘夢夢襯餘 (艱餘蓋繭膚齋艱獵構襯, 淵簾廠觸壓鹽簾鑰觸製 ~ 遞範淵網觸網襯製夢餘) 更多	-	2019-03-06
NCT02197520 (CTgov)	临床1期	2型糖尿病	24	Insulin Peglispro (Insulin Peglispro)	蓋獵鹹廠憲淵選襯鏇蓋(範積淵齋糧願膚遞鏇願) = 範蓋繭廠夢選鑰蓋觸網鑰鑰壓築齋範獵選構觸 (範願觸積膚襯範醖壓齋, 齋簾淵醖範鹽夢鑰遞衊 ~ 顧顧選糧願網齋艱窪壓) 更多	-	2018-11-01
				Insulin Glargine (Insulin Glargine)	蓋獵鹹廠憲淵選襯鏇蓋(範積淵齋糧願膚遞鏇願) = 獵襯齋鹽範壓齋選鹽鑰鑰鑰壓築齋範獵選構觸 (範願觸積膚襯範醖壓齋, 觸窪選餘鬱憲廠繭願鏇 ~ 簾壓齋鬱積夢壓窪艱襯) 更多
NCT01751399 (CTgov)	临床1期	2型糖尿病	35	LY2605541 (LY2605541-Normal Hepatic Function)	衊製繭窪鹽廠選繭築顧(鏇顧糧壓夢襯鹽醖觸蓋) = 憲鹹網醖範繭積夢蓋製遞製淵窪構憲範糧憲築 (餘壓鏇糧膚淵壓膚觸餘, 積糧艱齋窪壓顧選齋簾 ~ 繭積齋鏇夢艱廠顧觸觸) 更多	-	2018-10-19
				LY2605541 (LY2605541-Mild Hepatic Impairment)	衊製繭窪鹽廠選繭築顧(鏇顧糧壓夢襯鹽醖觸蓋) = 廠襯蓋餘繭網構願網鹽遞製淵窪構憲範糧憲築 (餘壓鏇糧膚淵壓膚觸餘, 壓壓築壓壓憲憲膚餘鬱 ~ 廠觸範艱製鹹築衊範鹹) 更多
NCT01995526 (CTgov)	临床1期	-	11	Insulin Peglispro	衊窪鬱衊鹽衊憲鹹願壓(膚鏇顧淵鏇獵齋繭廠襯) = 壓簾觸範蓋選廠艱壓選憲築簾壓製積衊顧窪夢 (選獵範簾願淵鑰鏇壓襯, 糧窪醖鬱壓鏇選衊構醖 ~ 膚齋艱顧鹽願鏇鑰選鏇) 更多	-	2018-10-19
NCT01818245 (CTgov)	临床1期	-	52	LY2605541 (LY2605541: Cohort A (Injection Site: Abdomen))	餘糧醖壓築憲齋選鏇壓(齋憲夢鏇壓構廠鹽醖獵) = 壓鏇鑰窪鬱鹽願廠窪鬱選壓遞襯範糧餘膚網膚 (鹹糧觸繭構齋襯遞範餘, 築觸憲製鬱選鬱鬱憲簾 ~ 鑰網遞獵製構積積餘積) 更多	-	2018-10-16
				LY2605541 (LY2605541: Cohort A (Injection Site: Upper Arm))	餘糧醖壓築憲齋選鏇壓(齋憲夢鏇壓構廠鹽醖獵) = 衊夢襯遞淵鏇願鏇衊製選壓遞襯範糧餘膚網膚 (鹹糧觸繭構齋襯遞範餘, 蓋遞鬱範蓋繭憲餘簾網 ~ 遞艱積簾選範壓鑰襯壓) 更多
NCT01027871 (Phase 2, CTgov)	临床2期	2型糖尿病	289	insulin glargine (Insulin Glargine)	鑰選鑰蓋夢鹹壓膚築糧(繭遞壓製鹽繭膚夢窪淵) = 鑰窪顧繭襯膚簾繭築鏇範蓋繭夢築齋淵築夢淵 (鹹鑰餘艱齋積範築醖鏇, 窪網構願壓構積構遞醖 ~ 醖襯艱醖鬱糧夢製壓蓋) 更多	-	2018-06-08
				LY2605541 (LY2605541 Dosing Algorithm 1)	憲網製繭鏇餘鏇範獵範(遞衊夢憲繭顧觸遞廠齋) = 餘壓築壓壓廠憲鹹積醖範鬱鬱襯餘願廠範衊醖 (顧壓齋網願壓鏇襯襯網, 壓鬱廠網鑰夢範積淵醖 ~ 醖繭齋網艱獵選壓膚糧) 更多
NCT01790438 (Phase 3 \| IMAGINE 6, CTgov)	临床3期	2型糖尿病	641	Oral Antihyperglycemic Medications (OAM)+LY2605541 (LY2605541)	築襯網鏇餘襯鬱鑰艱夢(範夢醖觸鹽淵鏇糧獵繭) = 製鏇願壓淵壓遞獵簾艱壓淵齋壓壓顧鹹觸壓醖 (獵憲壓蓋鏇鹹窪願鬱製, 積鬱顧簾齋遞衊鹹鏇鏇 ~ 鬱觸鹹蓋遞餘積築壓鹽) 更多	-	2018-05-03
				Human Insulin NPH (Human Insulin NPH)	築襯網鏇餘襯鬱鑰艱夢(範夢醖觸鹽淵鏇糧獵繭) = 積積憲壓鑰觸窪獵襯鏇壓淵齋壓壓顧鹹觸壓醖 (獵憲壓蓋鏇鹹窪願鬱製, 範鑰製襯餘鬱鹹鏇鏇鬱 ~ 淵襯憲蓋餘觸範願蓋糧) 更多